**PTC Therapeutics (PTCT)** saw its shares climb **7.2%** to **$78.53** during the last trading session, fueled by a strong trading volume. This uptick follows a **4.2%** increase over the prior four weeks. The company reported solid results for Q1 2026, likely bolstered by investor optimism surrounding its product **Sephience**, approved for treating phenylketonuria (PKU).
In its upcoming quarterly report, PTC Therapeutics is projected to announce earnings of **$0.11** per share, reflecting a **113.3%** increase year-over-year, alongside anticipated revenues of **$297.27 million**, up **66.2%** from the previous year. The consensus EPS estimate has notably been revised upward by **156%** in the past month, indicating potential price appreciation for the stock moving forward.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
